A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

Nicholas J. Short, Elias Jabbour, Kiran Naqvi, Ami Patel, Jing Ning, Koji Sasaki, Graciela M. Nogueras-Gonzalez, Prithviraj Bose, Steven M. Kornblau, Koichi Takahashi, Michael Andreeff, Gabriela Sanchez-Petitto, Zeev Estrov, Courtney D. Dinardo, Guillermo Montalban-Bravo, Marina Konopleva, Yesid Alvarado, Kapil N. Bhalla, Warren Fiskus, Maria KhouriRubiul Islam, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents'. Together they form a unique fingerprint.

Medicine & Life Sciences